About us

Leveraging cutting-edge
scientific research and technology

Who we are

ATAI is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering with mental health disorders.

Our mission

We are committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space.

Our approach

By pooling expertise, best practices, and resources across our entire portfolio, we mitigate risk and responsibly accelerate the development of impactful and evidence-based therapies.

Our news
Other news

Investors hope psychedelics are the new cannabis. Are they high?

In January atai Life Sciences, the German biotech company he founded last year, acquired a majority stake in Perception Neuroscience, a biopharmaceutical firm from New York which is developing a medication for pyschiatric conditions like depression from the drug, which is illegal in parts of the world.

read more »
Our Team

Vast experience
and great access to deal flow

Christian Angermayer
Founder
Florian Brand
Co-Founder and Chief Executive Officer
Matthias Luz, MD
Chief Medical Officer
Srinivas Rao, MD, PhD
Chief Scientific Officer
Greg Bates
Lead, Regulatory Affairs
Danny Talati
Lead, Business Development
Roman Dahl
Lead, Operations & Data
Aaron Weaver
Senior Legal Counsel
Simon Seibold
Assiociate
Ana Zarzosa
Team and Resarch assistant
Philipp Schreiber
Associate
Allan Malievsky
Associate
Ali Mahomed
Analyst
Careers

Work with us
to improve the lives of millions of people

WE ARE HIRING! Learn about career opportunities at ATAI and see open jobs across our platform companies.

Join the ATAI #InsightNetwork

Sign up below to receive the latest news on ATAI and innovations in the biotech and mental healthcare space